Targets › EPHX2
1 program from 1 company in 3 trials: 3 Phase 1; Neurology, Genitourinary; next expected readout Dec 2026.
Bifunctional enzyme. The C-terminal domain has epoxide hydrolase activity and acts on epoxides (alkene oxides, oxiranes) and arene oxides. (UniProt, P34913)
Open in Phaseline: the race on EPHX2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| EicOsis Human Health | EC5026 Soluble epoxide hydrolase (sEH) inhibitor | EPHX2 | Phase 1 | Parkinson's Disease (PD); Chronic Kidney Disease; Spinal Cord Injuries | Dec 2026 |
Parkinson's Disease (PD) (1) Chronic Kidney Disease (1) Spinal Cord Injuries (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.